Spinal Cord Stimulator Billing: The Trial-to-Implant Prior Authorization Guide

Why CPT 63650 Still Needs Prior Authorization While 63685 and 63688 Don't, and How NCD 160.7's Trial-First Rule Catches Billing Teams Off Guard

By Team Rcmaxis  ·  November 10, 2026  ·  12 min read

Here's the number that should stop every pain management biller cold: CPT 63650, the code for placing a spinal cord stimulator's trial electrodes, carries a national non-facility total RVU of 71.51, which works out to roughly $2,388.50 in professional-fee payment before any locality adjustment, using the 2026 non-qualifying-APM conversion factor of $33.4009. That's just the physician's cut. The facility side (OR time, the device itself, recovery) runs into the thousands more, billed separately by the hospital or ASC. One missing prior authorization number, and the entire claim, professional and facility both, can come back denied, regardless of how clinically justified the implant was.

Here's what makes this worse than a typical prior-auth miss: the rules changed, and a lot of practices are still billing off the old mental model. CMS used to require prior authorization for three spinal neurostimulator codes. It doesn't anymore. Get the current scope wrong in either direction, chasing authorization for a code that doesn't need it, or skipping it for the one that still does, and you've built a denial into your own workflow before the claim ever reaches the payer.

The Two-Phase Billing Problem: Trial, Then Permanent Implant

Spinal cord stimulation isn't billed as one procedure. It's structured as a trial phase and, if the trial works, a separate permanent implant phase, and each phase has its own code logic. The trial places temporary percutaneous leads, usually for about a week, without implanting the permanent battery. If the patient responds, the permanent implant follows: either the same percutaneous lead approach made permanent, or an open surgical placement of a paddle-style lead, plus the pulse generator itself.

Notice that 63685 almost always gets billed alongside either 63650 or 63655 on the same permanent-implant date of service, since the pulse generator doesn't do anything without leads attached to it. That pairing matters for the next section, because the two codes in that pair are treated completely differently when it comes to prior authorization.

Which SCS Codes Actually Need Prior Authorization Right Now

CMS added spinal neurostimulator implantation to its hospital outpatient department (OPD) prior authorization program back in July 2021, and at the time, the requirement covered more than one code. That's no longer true. CMS has since removed CPT 63685 and 63688 from the OPD prior-authorization list, stating the goal was to streamline the requirement. Only CPT 63650 still requires prior authorization, and only when it's performed in a hospital outpatient department. It isn't required in the inpatient hospital setting, and it isn't required at all for 63655, 63685, or 63688 under the current CMS list.

This is exactly the kind of rule that's easy to get backwards. A biller who remembers "SCS needs prior auth" from 2021 might still be submitting requests for 63685, which hasn't needed one in a while, while assuming 63650 is covered under some blanket neurostimulator exception it never actually got. Pull your last six months of SCS claims and check which codes you're actually requesting authorization for against the current list, not the one your team learned the process on.

NCD 160.7: What Medicare Actually Requires Before It Pays for the Permanent Device

Prior authorization is the procedural gate. National Coverage Determination 160.7, Electrical Nerve Stimulators, is the substantive one, and it's been in effect since 1995 with the same core standard: spinal cord stimulation is covered for chronic, intractable pain, and only as a late or last-resort treatment after more conservative options have been tried and failed. That "last resort" framing isn't just language auditors ignore. It's the documentation test your chart needs to pass.

In practice, that means your documentation trail needs three things before a permanent implant claim goes out: a record of the conservative treatments already tried and why they didn't work, a psychological or psychiatric evaluation ruling out significant unaddressed psychiatric comorbidity that could confound the trial results, and objective evidence from the trial period itself. The trial evidence standard most Medicare contractors and device manufacturers point practices toward is a documented reduction of at least 50% in the target pain level, or an equivalent reduction in analgesic medication use, measured and recorded, not just summarized as "patient reports improvement."

Devices Under an IDE Study Get an Extra Layer

If the device or a specific use case is still under an FDA Investigational Device Exemption study, that implant has to separately meet NCD 160.7's coverage criteria on top of whatever the IDE study protocol requires. Don't assume IDE participation substitutes for the standard Medicare medical-necessity documentation. It adds a layer; it doesn't replace one.

Where These Claims Actually Get Denied

Audit Exposure: Why SCS Claims Draw Extra Scrutiny

Spinal cord stimulators sit in a category Medicare contractors and commercial payers watch closely for a straightforward reason: they're high-cost implants with a documentation standard that's easy to shortcut under time pressure, and the device itself doesn't disappear if the medical necessity case turns out to be weak. Post-payment medical review on implant claims typically reaches back through the standard Medicare lookback window, and the most common recoupment trigger isn't fraud, it's incomplete trial documentation: missing the quantified pain-reduction figure, missing the psych evaluation, or missing a clear record of what conservative care was tried first.

Commercial payers frequently layer their own, sometimes stricter, requirements on top of NCD 160.7, including mandatory trials of physical therapy or injection therapy before they'll authorize an SCS evaluation at all. Local Coverage Determinations from your Medicare Administrative Contractor can also add detail the national NCD doesn't specify. Treat the national NCD as the floor, not the full requirement, and check your specific MAC's current LCD and your top commercial payers' medical policies before assuming the national standard is all you need to satisfy.

Frequently Asked Questions About Spinal Cord Stimulator Billing

Does CPT 63685 need Medicare prior authorization for a spinal cord stimulator?

No, not anymore. CMS pulled CPT 63685 (insertion or replacement of the pulse generator) and CPT 63688 (revision or removal) off the hospital outpatient department prior authorization list. Only CPT 63650, the percutaneous electrode placement code, still requires prior authorization in that setting. A lot of billing teams still request prior auth for codes that no longer need it, or worse, skip it for 63650 because they assume the whole category was removed.

What's the billing difference between an SCS trial and the permanent implant?

The trial uses CPT 63650 to place temporary percutaneous leads for a short test period, typically without implanting the permanent pulse generator. The permanent implant adds CPT 63685 for the pulse generator itself, plus either 63650 again (percutaneous lead) or 63655 (open laminotomy placement of a paddle lead), depending on the surgical approach. If both the trial and the permanent implant happen during the same hospital outpatient encounter, one prior authorization request covers both; if the trial happens in a physician office or ASC and the permanent implant later happens in a hospital outpatient department, that permanent encounter needs its own separate prior authorization for 63650.

How much pain relief does a patient need during the SCS trial before Medicare approves the permanent device?

NCD 160.7 doesn't set one universal percentage in the text of the policy itself, but the standard most Medicare contractors and device manufacturers point to is a documented reduction of at least 50% in the target pain level, or an equivalent reduction in analgesic medication use, recorded during the trial period. The documentation needs to show the actual before-and-after comparison, not just a note that the patient felt better.